ArticleArchives of endocrinology and metabolism2017
Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study.
Article in Archives of endocrinology and metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Recent Advances in the Treatment of Thyroid Pathologies with Selenium-Containing Compounds, Nanoparticles and Nanocomplexes Based on Selenium and Selenoproteins.Biological trace element research · 2026Review
- Baseline selenium is associated with response to intravenous Methylprednisolone with selenium supplementation for thyroid eye disease in a selenium-sufficient area.Scientific reports · 2025Article
- Thyroid Health and Selenium: The Critical Role of Adequate Intake from Fetal Development to Adolescence.Nutrients · 2025Review
- Evaluation of selenoproteins and proinflammatory cytokines in L-thyroxine-induced hyperthyroid rats: effects of selenium supplementation.Archives of endocrinology and metabolism · 2025Article
- Selenium and thyroid diseases.Frontiers in endocrinology · 2023Review
- Selenium level correlates negatively with antibodies but positively with thyroid function in children with down syndrome: an Indonesian study.Frontiers in endocrinology · 2023Article
- The risk factors for Graves' ophthalmopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Review
- Selected Essential and Toxic Chemical Elements in Hypothyroidism-A Literature Review (2001-2021).International journal of molecular sciences · 2021Review
- Plasma levels of Th17-associated cytokines and selenium status in autoimmune thyroid diseases.Immunity, inflammation and disease · 2021Article
- Evaluation of Serum Selenium Status by Age and Gender: A Retrospective Observational Cohort Study in Western Romania.Nutrients · 2021Observational
- Role of Selenium Deficiency in Pediatrics with Acquired Hypothyroidism.International journal of preventive medicine · 2021Article
- Serum Selenium Status and Its Interrelationship with Serum Biomarkers of Thyroid Function and Antioxidant Defense in Hashimoto's Thyroiditis.Antioxidants (Basel, Switzerland) · 2020Article
- A Systematic Review on the Role of Antioxidants in Thyroid Eye Disease.Journal of current ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSelenium (Se) supplementation has been used to help prevent the progression of Graves' ophthalmopathy (GO) and autoimmune thyroid diseases (AITD) patients. We investigated Se serum and selenoprotein P (SePP) levels in Graves' disease (GD) with and without GO, Hashimoto's thyroiditis (HT) patients and in 27 control individuals (C). SUBJECTS AND
methodsWe studied 54 female and 19 male patients: 19 with GD without GO, 21 GD with GO, 14 with HT and 19 with HT+LT4. Se values were measured using graphite furnace atomic absorption spectrophotometry. Serum SePP levels were measured by ELISA.
resultsMedian Se levels were similar among all groups; GD patients: 54.2 (46.5-61.1 μg/L), GO: 53.6 (43.5-60.0 μg/L), HT: 51.9 (44.6-58.5 μg/L), HT+LT4 54.4 (44-63.4) and C group patients: 56.0 (52.4-61.5 μg/L); P = 0.48. However, serum SePP was lower in GO patients: 0.30 (0.15-1.05 μg/mL) and in HT patients: 0.35 (0.2-1.17 μg/mL) compared to C group patients: 1.00 (0.564.21 μg/mL) as well as to GD patients: 1.19 (0.62-2.5 μg/mL) and HT+LT4 patients: 0.7 (0,25-1.95); P = 0.002. Linear regression analysis showed a significant relationship between SePP and TPOAb values (r = 0.445, R2 = 0.293; P < 0.0001). Multiple regression analysis found no independent variables related to Se or SePP.
conclusionA serum Se concentration was lower than in some other countries, but not significantly among AITD patients. The low serum SePP levels in GO and HT patients seems to express inflammatory reactions with a subsequent increase in Se-dependent protein consumption remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.